Pharmaniaga Berhad 467709-M Incorporated In Malaysia

V. NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

8. Operating segments

In the prior year's audited consolidated financial statements, the basis of segmentation was on a primary format of business segments and a secondary format of geographical segment. In the current period ended 30 September 2010 and for the current financial year ending 31 December 2010, the basis of segmentation was changed to operating segments based on information reported internally to the Managing Director of the Company.

Operating Segment information for the current financial period to 30 September 2010 is as follow:

	Pharmaceutical manufacturing RM'000	Pharmaceutical trading, marketing and distribution RM'000	Medical products and services RM'000	Other operations RM'000	Elimination RM'000	Total RM'000
Revenue						
External revenue	384	1,000,561	1,287	-	-	1,002,232
Inter-segment revenue	104,103	5,324	133	44,013	(153,573)	-
Total revenue	104,487	1,005,885	1,420	44,013	(153,573)	1,002,232
Results						
Segment results	16,281	35,337	(633)	38,181	(32,696)	56,470
Unallocated corporate expenses						(5,383)
Profit from operations						51,087
Interest expense	-	(2,695)	-	(946)	806	(2,835)
Interest income	-	852	-	806	(806)	852
Share of results of associate						(941)
Profit before income tax						48,163
Income tax						(14,701)
zakat						(1,200)
Profit for the period						32,262
Attributable to: Owners of the Parent Minority interest Profit for the period						32,640 (378) 32,262

9. Material events subsequent to the end of the current financial period

In the opinion of the Directors, there are no items, transactions or events of a material and unusual nature which have arisen since 30 September 2010 to the date of this announcement which would substantially affect the financial results of the Group for the nine months ended 30 September 2010 that have not been reflected in the condensed financial statements.